Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients. A Cohort Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Apnea, Obstructive Sleep
- Sponsor
- Parc Taulí Hospital Universitari
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Immunological study: cytokines.
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Sleep is an important modulator of the immune response, whereby sleep disturbances (ie, poor sleep quality, insufficient sleep and/or primary sleep disorder, obstructive sleep apnea (OSA)) contribute to inflammatory disease risk and dysregulation of immune response in front of infectious agents.
The objective of this study is to evaluate the impact of undiagnosed and non-treated sleep disorders on innate immunity in a cohort of COVID-19 patients and the role of trained immunity induced by influenza vaccination in the innate immune response.
Detailed Description
Sleep and immune system have reciprocal relationship. Sleep has a restorative role on immune system, influencing innate and adaptive immunity and sleep disorders can decrease immune response. Healthy innate immunity is crucial into regulation of the response against SARS-CoV-2. The hypothesis of the study is that the innate immunity response is blunted by sleep disorders and, this mitigated immune response, could influence on COVID-19 severity. Impaired immune response in patients with sleep disorders could be ameliorated inducing trained immunity by influenza vaccine.
Investigators
Andrea Grau Freixinet
Pulmonology medical specialist
Parc Taulí Hospital Universitari
Eligibility Criteria
Inclusion Criteria
- •Participants over 18 years old with diagnosis of COVID-19 during first year of coronavirus pandemic in March-June 2021.
Exclusion Criteria
- •\>70 years and \<18 years
- •Recent COVID-19 (\<6 months)
- •Other infection (\<3 months)
- •Obstructive sleep apnea in treatment with CPAP prior to COVID infection.
- •Immunosuppressed
Outcomes
Primary Outcomes
Immunological study: cytokines.
Time Frame: To evaluate immune response blood samples will be taken at the time influenza vaccine is given, 7 and 30 days later.
To measure in blood: IL-1 beta, IL-6, IL-8, IL-10, TNF-alfa, IFN-alfa, IFN-gamma, GM-CSF.
Secondary Outcomes
- Epigenetic modification.(To evaluate immune response blood samples will be taken at the time influenza vaccine is given, 7 and 30 days later.)
- Innate cells: monocytes, classical dendritic cells and Natural Killer cells.(To evaluate immune response blood samples will be taken at the time influenza vaccine is given, 7 and 30 days later.)
- Diagnostic of obstructive sleep apnea in selected cohort(It is an overnight study that will last for one night.)